MedtronicMDT
MDT
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
49% more first-time investments, than exits
New positions opened: 226 | Existing positions closed: 152
2% more funds holding
Funds holding: 2,037 [Q3] → 2,073 (+36) [Q4]
1.7% more ownership
Funds ownership: 81.28% [Q3] → 82.97% (+1.7%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 31 [Q3] → 31 (+0) [Q4]
7% less call options, than puts
Call options by funds: $586M | Put options by funds: $632M
11% less capital invested
Capital invested by funds: $95.9B [Q3] → $85B (-$10.8B) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 773 | Existing positions reduced: 875
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$91
2%
upside
Avg. target
$100
12%
upside
High target
$107
20%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Citigroup Joanne Wuensch 43% 1-year accuracy 22 / 51 met price target | 20%upside $107 | Buy Upgraded | 4 Mar 2025 |
RBC Capital Shagun Singh 63% 1-year accuracy 42 / 67 met price target | 18%upside $105 | Outperform Reiterated | 19 Feb 2025 |
UBS Danielle Antalffy 46% 1-year accuracy 6 / 13 met price target | 7%upside $95 | Neutral Maintained | 19 Feb 2025 |
Baird David Rescott 75% 1-year accuracy 12 / 16 met price target | 2%upside $91 | Neutral Maintained | 19 Feb 2025 |
Financial journalist opinion
Based on 21 articles about MDT published over the past 30 days
Negative
Investors Business Daily
6 hours ago
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.
Neutral
The Motley Fool
11 hours ago
2 Recession-Proof Dividend Stocks to Buy and Hold
Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen.
Neutral
Zacks Investment Research
2 days ago
Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?
Medtronic's Hypertension business is on the brink of a major expansion, driven by its Simplicity blood pressure procedure.
Positive
Zacks Investment Research
3 days ago
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Positive
Zacks Investment Research
5 days ago
Investors Heavily Search Medtronic PLC (MDT): Here is What You Need to Know
Medtronic (MDT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Positive
Zacks Investment Research
1 week ago
Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue?
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Positive
Seeking Alpha
1 week ago
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Upgraded Medtronic to a ‘Buy' rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth, highlighting significant momentum in its Cardiac Ablation Solutions business. The company's structural heart business, especially the Evolut FX+ TAVR system, is showing strong adoption and competitive advantages over Edwards Lifesciences's SAPIEN TAVR product.
Positive
Zacks Investment Research
1 week ago
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan
Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions.
Negative
Reuters
1 week ago
FDA classifies recall of Medtronic embolization devices as 'most serious'
The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", following reports of the deaths of four patients.
Positive
Seeking Alpha
1 week ago
Dividend Kings Of The Future
A list of 9 companies that may reach Dividend King status in the near future. These companies span various sectors and offer investors a wide range of dividend growth rates and yields. A few of these companies have abnormally high payout ratios, which may hinder their ability to achieve Dividend King status.
Charts implemented using Lightweight Charts™